Semaglutide vs Tirzepatide

Side-by-Side Comparison

Which One Should You Choose?

Semaglutide and tirzepatide are both injectable peptides used for weight management and blood sugar control, but they work through different mechanisms. Semaglutide activates only the GLP-1 receptor, while tirzepatide activates both GLP-1 and GIP receptors. This dual-agonist approach appears to produce greater weight reduction in clinical trials.

In the SURMOUNT-5 head-to-head trial, tirzepatide demonstrated statistically superior weight loss compared to semaglutide at maximum doses. However, semaglutide has a longer real-world safety track record and more long-term data available.

Use This Decision Framework

Choose semaglutide if: you want the longest real-world track record, need an oral option, or want the lower-cost entry point.

Choose tirzepatide if: you want the strongest average weight-loss data, have plateaued on semaglutide, or your provider prefers the dual-agonist approach.

Need the broader GLP-1 reference set first? Start with the GLP-1 calculator hub, then branch into the individual calculators.

Ready to calculate your dose? Use our semaglutide calculator or tirzepatide calculator.

How the Mechanisms Actually Differ

Both compounds are incretin mimetics, meaning they imitate gut hormones that the body releases after eating. The difference is how many of those hormone pathways each one touches.

Semaglutide is a GLP-1 receptor agonist. It acts on a single pathway, and that pathway does several things at once: it slows gastric emptying so food stays in the stomach longer, it signals satiety in the hypothalamus, and it increases glucose-dependent insulin secretion. The glucose-dependent part matters, because it means insulin release rises when blood sugar is elevated rather than continuously, which is why GLP-1 agonists alone carry a relatively low hypoglycemia risk.

Tirzepatide adds a second pathway. Alongside GLP-1 activity it also agonizes the GIP receptor. GIP is the other major incretin hormone, and the working hypothesis is that combined GIP and GLP-1 activity affects appetite regulation and fat metabolism through partly complementary routes. That combination is the mechanistic argument for why the dual agonist tends to produce larger average reductions in trials.

One consequence of the different mechanisms is that the milligram numbers are not comparable. Tirzepatide's 15 mg maximum is not "six times stronger" than semaglutide's 2.4 mg maximum. They are different molecules with different receptor affinities and different potency per milligram. Comparing dose numbers across the two compounds is a common misreading and tells you nothing useful.

Side Effects and Tolerability

The side effect profiles overlap heavily, and both are dominated by gastrointestinal effects: nausea, diarrhea, constipation, vomiting, and reduced appetite. For both compounds these effects are most pronounced in the weeks immediately following a dose increase, and they typically ease as the body adjusts.

This is the entire reason both products use a slow escalation schedule rather than starting at an effective dose. The starting dose of each is not intended to be therapeutic. It exists to let tolerance build. Escalating faster than the labeled schedule tends to trade a few weeks of time for considerably worse nausea, and is a common cause of people abandoning treatment early.

Both carry a boxed warning regarding thyroid C-cell tumors based on rodent studies, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Both also carry warnings around pancreatitis and gallbladder disease. These are not areas for self-assessment, and they are a large part of why the choice between the two belongs with a clinician who knows your history.

Cost and Access

Cost comparison depends heavily on which route is being discussed, and the two routes are not equivalent. Through licensed prescription channels, both are branded products with pricing set by the manufacturer and heavily mediated by insurance coverage, which frequently differs between the two even for the same patient.

The compounded and research-supply figures shown in the table above reflect a different and far less regulated market, where product identity, purity, and concentration are not verified by the same standards. A lower per-vial number in that column is not a like-for-like saving, because what is in the vial is not established the same way. Anyone weighing the cost difference should weigh that gap alongside it.

Switching Between Them

Switching is not a matter of matching milligrams, because the milligram scales are not equivalent. Standard practice when moving between incretin therapies is to restart escalation on the new compound rather than attempting to jump to a dose that feels equivalent to the previous one. Tolerance to one does not fully transfer to the other, and the GI effects tend to reappear on the new molecule.

The most common reason people consider switching is a weight loss plateau on semaglutide at or near maximum dose. That is a legitimate clinical conversation, and it is also one where the answer is sometimes not a switch at all, since plateaus have several causes unrelated to the compound. This is a decision to bring to a prescriber rather than resolve from a comparison table.

Frequently Asked Questions